Please login to the form below
Foundation Medicines
This page shows the latest Foundation Medicines news and features for those working in and with pharma, biotech and healthcare.
US start-up EQRx promises approach that will slash drug prices
in 2018 – and Blueprint Medicines which has just claimed its first approval for a high-priced cancer drug. ... Other key figures in EQRx include former Foundation Medicine and McKesson executive Melanie Nallicheri, who serves as president and chief
Latest news
-
AstraZeneca to develop Lynparza companion diagnostic
To do so AZ has joined forces with molecular information firm Foundation Medicines, whose FoundationOne genomic profiling platform will be used to develop the test. ... Nina Mojas, global medicine lead for Lynparza at AstraZeneca, said: “Utilising
-
The distance travelled
When medicines were approved, the community thought that prices were too high and wanted a greater say in the development and delivery of medicines. ... Unimaginable thirty years ago, most companies now collaborate with not-for-profit organisations like
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Interview: Harvey Berger and Timothy Clackson, Ariad
treatments.”. It's the results of strategy to “discover, develop and deliver our medicines without the additional input of pharma partners”, says Berger. ... We are building a strong commercial presence, but it is one that is built on what
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%
- Communique - Communiqué Awards
- GSK launches late-stage testing of RSV vaccine candidate in older adults
- AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly
- FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
- FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
- UK introduces Rare Diseases Framework to improve the lives of people with rare diseases
- Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease
- UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’
- Merck to acquire Pandion Therapeutics for $1.85bn
- bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video
PMHub
Fishawack Group of Companies
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...
Latest intelligence
- 4 ways to recruit Alzheimer’s disease patients for your clinical trial
- What key things do you need to remember to reach patients living with Alzheimer’s disease?...
- Integrating competitive intelligence into business development, licensing and M&A strategy
- The advantages of partnering with a competitive intelligence or knowledge management team...
- Reaching patients and HCPs during the pandemic
- COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
Quick links
Infographics
